Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad to Participate in Upcoming September 2019 Conferences

Celyad to Participate in Upcoming September 2019 Conferences

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program